Coherence Bio builds a modular benchtop automation product for cell-based assays and imaging, designed for teams that need reliable biology without building a full robotics line. Modern drug discovery is increasingly “small-batch, high-value”: fewer experiments, but each one must be trustworthy and repeatable. 

Keystone compresses what is normally a scattered workflow into a single instrument that can run multi-day assays with consistent timing and conditions, and outputs a complete run history so teams can debug, compare, and reuse protocols instead of reinventing them. It’s a practical upgrade for AI biotechs, CROs, and research groups that want faster weekly learning cycles, less manual labor, and fewer reruns. 

Our team blends medical-device engineering, optics, embedded systems, and assay workflows, focused on shipping integrated systems. We aim to make advanced cell experiments as dependable as modern software pipelines.

Keystone is a sealed, modular benchtop system that automates end-to-end multi-day cell workflows inside one controlled enclosure. It combines culture environment control, multi-channel fluid handling for media exchange and dosing, and scheduled longitudinal imaging for continuous readouts. 

Protocols are configured as software templates (timing, dosing maps, imaging schedules) and executed reproducibly across runs. The platform supports workflows such as phenotypic screening, 2D cytotoxicity dose-response, and 6-day organoid growth with dosing and time-lapse imaging, and can incorporate optional endpoint assays (e.g., ATP/MTT) when needed. 

AI-enabled analysis modules quantify time-series image features and response trends, turning raw runs into interpretable metrics and improving quality control. Each run captures operational context (actions, key conditions, protocol version, time-series outputs) to enable cross-batch comparison, troubleshooting, and downstream modeling. The architecture expands via sterile consumables and modular upgrades.

1. Seeking introductions to early-stage investors interested in biotools, AI-driven biotech and lab automation, particularly those supporting seed-stage startups.

2. Build strategic partnerships with lab automation leaders and US CROs to co-validate workflows, establish reference sites, and create a distribution/service path.